After disappointing trial results for cancer treatments, Mural Oncology announced Wednesday it is cutting 90% of its workforce.

After a lengthy regulatory back-and-forth, Eisai and Biogen's Alzheimer's drug is on the market in Europe. Elsewhere, Sarepta will start testing a new gene therapy for limb-girdle muscular dystrophy.

Mural Oncology stock skyrockets after it begins exploring strategic alternatives to maximize shareholder value after the failure of two cancer studies for nemvaleukin alfa.

Mural Oncology is halting development of its lead IL-2 therapy and enacting major layoffs after its second trial failure this ...

US biotech Mural Oncology has halted all development of its lead candidate, nemvaleukin alfa, after the engineered cytokine ...

In a report released yesterday, Judah Frommer from Morgan Stanley maintained a Hold rating on Mural Oncology Plc (MURA – Research Report). The ...

Shares of Mural Oncology plc (NASDAQ: MURA) are soaring Monday following the company's announcement that it will discontinue clinical development of its lead drug candidate Nemvaleukin and begin ...

Mural Oncology plc said on Tuesday it would stop clinical development of its lead cancer treatment, nemvaleukin, and look ...

Citigroup Inc. C +3.20% + Free Alerts posted better-than-expected earnings for its first quarter. Citigroup reported quarterly earnings of $1.96 per share which beat the analyst consensus estimate of ...

Real-time index price for TSX 60 Index (TXSX), along with buy or sell indicators, analysis, charts, historical performance, ...

April 15, 2025 (Investorideas.com Newswire) Investorideas.com ( www.investorideas.com ), a go-to platform for big investing ideas for stock traders, including biotech stocks reports on trading and ...

Boston and Dublin biotech Mural Oncology is laying off nearly all of its employees and ending clinical development of its IL-2 drug nemvaleukin alfa.